| Order number | Description | Quantity | Delivery time | CE |
|---|---|---|---|---|
| TB 203-A | G-6-PDH deficiency screening Kit | 5x10 tests | 15-20 days | x |
G-6-PDH deficiency screening KitTrinity Biotech Glucose-6-Phosphate Dehydrogenase reagents are for the qualitative, visual fluorescence screening of G-6-PDH in whole blood. Samples which have been determined deficient or intermediate should be assayed by a quantitative G-6-PDH method such as Trinity Biotech Procedure No. 345-UV. G-6-PDH deficiency in red cells has been demonstrated to be the basis for certain drug-induced hemolytic anemias. Tarlov et al. points out the importance of identifying individuals with this biochemical defect as an aid in the selection of therapeutic agents. Severe hemolytic anemia may result in these individuals when they are given many commonly used drugs. The majority of subjects who have demonstrated G-6-PDH deficiency are clinically normal until exposed to one of several oxidant drugs (anti-malarial drugs, sulfa drugs, ascorbic acid and others). This defect should be considered whenever an otherwise unexplained case of hemolytic anemia is encountered. Red cell G-6-PDH deficiency has been found in about 13% of African- American males and in about 3% of African-American females. The incidence is also high among other racial and ethnic groups, such as Sardinians, Greeks and Sephardic Jews. For semi-quantitative purposes, Beutler first suggested estimating glucose-6-phosphate dehydrogenase (G-6-PDH, EC 1.1.1.49) in terms of visual appearance of fluorescence in red cell-substrate mixtures. The test is performed by incubating a small amount of blood with glucose- 6-phosphate and nicotinamide adenine dinucleotide phosphate (NADP). Drops of the mixture are removed at 5-minute intervals, spotted on filter paper and then viewed under long-wave ultraviolet light. Fluorescence is clearly evident in mixtures prepared from normal blood, whereas deficient samples yield little or no fluorescence. |
Additional Documentation
|
Login